Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/04/25
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in AustraliaGlobeNewsWire • 03/03/25
Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 02/25/25
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4GlobeNewsWire • 02/18/25
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing TransactionsGlobeNewsWire • 12/18/24
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in IsraelGlobeNewsWire • 12/12/24
ESPR Files New Drug Submissions for Nexletol & Nexlizet in CanadaZacks Investment Research • 12/03/24
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024GlobeNewsWire • 11/18/24
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/07/24
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 11/07/24
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 10/31/24
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?Zacks Investment Research • 09/11/24
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)GlobeNewsWire • 09/03/24